Observation of the Curative Effect of the Dexamethasone Vitreous Cavity Implant for the Treatment of Irvine-Gass Syndrome  

作　　者：MAO Yu GAO Li Qin JIA Li Yun HOU Si Meng XIAO Yuan Yuan JI Xi Wen WANG Shuang 

机构地区：[1]Beijing Tongren Eye Center,Beijing Ophthalmology and Visual Science Key Lab,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China [2]Beijing Institute of Ophthalmology,Beijing Tongren Eye Center,Beijing Ophthalmology and Visual Science Key Lab,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China

出　　处：《Biomedical and Environmental Sciences》2023年第8期725-731,共7页生物医学与环境科学（英文版）

摘　　要：Objective To investigate the clinical efficacy of dexamethasone vitreous cavity implants(Ozurdex)for the treatment of macular edema(Irvine-Gass Syndrome)after cataract surgery.Method Eight patients(eight eyes)with Irvine-Gass syndrome were enrolled for vitreous injections with Ozurdex.The patients included six men(six eyes)and two women(two eyes)with a mean age of 67.12±11.92 years.Changes in the patients best-corrected visual acuity(BCVA),central macular thickness(CMT),and intraocular pressure were compared before and after treatment.Result The mean visual acuity BCVA of the patients was 0.81±0.26 before implantation,which improved to 0.20±0.12,0.13±0.09,and 0.15±0.13 at 2 weeks,1 month,and 3 months after implantation,respectively(P<0.001).The patient’s mean CMT before implantation was 703.00±148.88μm,and it reduced to 258.87±37.40μm,236.25±28.74μm,and 278.00±76.82μm at 2 weeks,1 month,and 3 months after implantation,respectively(P<0.001).Conclusion The dexamethasone vitreous cavity implant(Ozurdex)is a safe and effective treatment,which can effectively improve patient’s visual acuity and reduce macular edema associated with cataract surgery.

关 键 词：Irvine-Gass Syndrome Macular edema DEXAMETHASONE Vitreous injection 

分 类 号：R779.66[医药卫生—眼科]